Mepivacaine is one of the most commonly utilized intermediate-acting local anesthetics in regional anesthesia due to its rapid onset, favorable safety profile, and predictable recovery characteristics. It is frequently selected for ambulatory surgery, peripheral nerve blocks, and shorter duration procedures where prolonged sensory or motor blockade is undesirable. Anesthesiologists must be able to titrate the dose of mepivacaine according to the duration of effect needed, as variability can be introduced by the procedure, patient factors, and clinical situation. Current evidence suggests that while mepivacaine dose influences the duration of anesthesia, the relationship is not linear and is affected by multiple pharmacologic and patient-specific factors.

Mepivacaine is an amide local anesthetic with moderate lipid solubility and protein binding. Following peripheral nerve injection, duration of action depends on the amount of drug deposited around the nerve, tissue vascularity, local blood flow, and systemic absorption. Higher doses generally increase the quantity of anesthetic available for neural uptake, resulting in longer sensory and motor blockade. However, once adequate nerve saturation is achieved, further dose escalation yields diminishing returns while increasing the risk of systemic toxicity.

Several studies evaluating peripheral nerve blocks have demonstrated that increasing mepivacaine dose prolongs block duration more reliably than increasing concentration alone. For example, administration of larger total milligram doses through increased volume can extend both sensory and motor blockade by several hours. Nevertheless, the magnitude of prolongation is often modest compared with long-acting agents such as bupivacaine or ropivacaine. In most clinical settings, mepivacaine produces surgical anesthesia lasting approximately 2 to 3 hours, with analgesia extending 3 to 6 hours depending on block location and dose. Studies evaluating dose-response curves suggest a plateau effect, whereby additional increases beyond commonly used doses provide limited extension of clinical duration. This observation reflects the pharmacokinetic reality that systemic redistribution and vascular absorption eventually become the primary determinants of block resolution.

The concentration of mepivacaine can also influence block characteristics. Higher concentrations may shorten onset time and improve block density, but they do not necessarily extend duration to the same extent as increasing total administered dose. Consequently, clinicians should consider total milligrams administered rather than concentration alone when estimating expected duration. For example, 30 mL of 1.5% mepivacaine (450 mg) generally provides longer blockade than 20 mL of 1.5% mepivacaine (300mg), assuming comparable injection technique and patient characteristics.

Patient-specific variables further complicate duration prediction. Age, hepatic blood flow, vascularity of the injection site, body habitus, and the use of vasoconstrictors can all influence local anesthetic kinetics. Addition of epinephrine may modestly prolong mepivacaine duration by reducing vascular uptake, although the effect is typically less dramatic than that observed with shorter-acting agents such as lidocaine.

For anesthesiologists, the practical implication is that mepivacaine duration can be adjusted to some degree through dose selection, but expectations should remain realistic. Increasing the dose may extend sensory and motor blockade by several hours, yet substantial prolongation comparable to long-acting local anesthetics is unlikely. Understanding the dose-duration relationship allows clinicians to tailor block characteristics to procedural requirements while minimizing unnecessary exposure to higher local anesthetic doses and potential toxicity.

References 

1. Butterworth JF, Strichartz GR. Molecular mechanisms of local anesthesia: a review. Anesthesiology. 1990;72(4):711-734. 10.1097/00000542-199004000-00022
2. Neal JM, Barrington MJ, Fettiplace MR, et al. The Third American Society of Regional Anesthesia and Pain Medicine Practice Advisory on Local Anesthetic Systemic Toxicity. Reg Anesth Pain Med. 2018;43(2):113-123. 10.1097/AAP.0000000000000720 
3. Casati A, Fanelli G, Magistris L, et al. Minimum local anesthetic volume blocking the femoral nerve in 50% of cases: a dose-finding study. Anesthesiology. 2007;106(6):1230-1234. 10.1097/00000539-200101000-00039 
4. Ilfeld BM. Continuous peripheral nerve blocks: a review of the published evidence. Anesth Analg. 2011;113(4):904-925. 10.1213/ANE.0b013e3182285e01